問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳焜結
下載
2017-02-10 - 2025-12-31
Condition/Disease
Test Drug
Participate Sites15Sites
Recruiting13Sites
未分科
Division of Hematology & Oncology
2024-04-01 - 2027-05-31
Participate Sites6Sites
Recruiting6Sites
2020-09-15 - 2026-10-01
Participate Sites4Sites
Recruiting4Sites
2023-08-01 - 2027-04-30
2024-09-01 - 2029-02-05
Participate Sites8Sites
Not yet recruiting4Sites
2024-01-15 - 2029-12-31
Participate Sites5Sites
Recruiting5Sites
2018-08-01 - 2026-12-01
Participate Sites9Sites
Recruiting8Sites
2024-03-28 - 2026-08-28
2024-11-29 - 2027-09-30
2019-04-01 - 2022-12-31
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Division of General Internal Medicine
全部
